Kyowa Kirin
Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Drug Rocatinlimab
Amgen; Kyowa Kirin; rocatinlimab; atopic dermatitis; OX40 receptor; ASCEND trial; ROCKET program; long-term safety; eczema
Kyowa Kirin Invests $330M in Kura’s Leukemia Drug, Gaining Shared Rights Ahead of FDA Submission
Kyowa Kirin, Kura, leukemia drug, FDA submission, pharmaceutical investment
Kyowa Kirin Divests China Unit and Reduces Small-Molecule Discovery Efforts
Kyowa Kirin, China business, small-molecule discovery, restructuring, Asia Pacific, pharmaceuticals
Kyowa Kirin Invests $530M in First North American Biologics Manufacturing Facility
Kyowa Kirin, biologics manufacturing, North America, investment, North Carolina